Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Casebia and CRISPR jointly license cell engineering technology from MaxCyte

Executive Summary

MaxCyte Inc. licensed CRISPR Therapeutics AG and Casebia Therapeutics nonexclusive rights to its cell engineering platform Flow Electroporation. MaxCyte agreed to supply this system to the partners.
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
    • Synthesis Technologies, Production Processes
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Intra-Biotech Deal
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register